Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight

Next Previous
Trial Profile

Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms STEP Young
  • Sponsors Novo Nordisk

Most Recent Events

  • 18 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 06 Aug 2024 Planned End Date changed from 15 Jan 2027 to 7 Dec 2026.
  • 06 Aug 2024 Planned primary completion date changed from 7 Nov 2025 to 29 Sep 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top